This is a StreetInsider.com Premium Only Page

Protalix BioTherapeutics (PLX) –

Apr 3, 2024 05:31 PM Form 4 Protalix BioTherapeutics For: Apr 01 Filed by: Bashan Dror

Mar 14, 2024 07:04 AM Form 10-K Protalix BioTherapeutics For: Dec 31

Mar 14, 2024 06:58 AM Form 8-K Protalix BioTherapeutics For: Mar 14

Mar 14, 2024 06:50 AM Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

Mar 7, 2024 06:50 AM Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Feb 23, 2024 06:50 AM Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Jan 2, 2024 06:36 AM Form SC 13G/A Protalix BioTherapeutics Filed by: NACHT MARIUS

Dec 26, 2023 06:56 AM Form 8-K Protalix BioTherapeutics For: Dec 26

Dec 26, 2023 06:50 AM Protalix BioTherapeutics (PLX) Issues 2024 Letter to Stockholders

Dec 26, 2023 06:50 AM Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Nov 6, 2023 07:51 AM Form 10-Q Protalix BioTherapeutics For: Sep 30

Nov 6, 2023 07:23 AM Form 8-K Protalix BioTherapeutics For: Nov 06

Nov 6, 2023 06:54 AM Protalix BioTherapeutics (PLX) Reports In-Line Q3 EPS

Nov 6, 2023 06:50 AM Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results

Oct 31, 2023 06:43 AM Protalix BioTherapeutics (PLX) PT Raised to $10 at H.C. Wainwright

Oct 30, 2023 06:50 AM Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

Oct 20, 2023 06:50 AM Form 4 Protalix BioTherapeutics For: Oct 19 Filed by: Bashan Dror

Oct 9, 2023 06:50 AM Protalix BioTherapeutics (PLX) Issues Statement Regarding Security Situation in Israel

Oct 9, 2023 06:50 AM Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel

Oct 3, 2023 05:01 PM Form 4 Protalix BioTherapeutics For: Sep 29 Filed by: Ben Zvi Shmuel

Oct 3, 2023 05:01 PM Form 4 Protalix BioTherapeutics For: Sep 29 Filed by: Melincoff Gwen A

Oct 3, 2023 05:01 PM Form 4 Protalix BioTherapeutics For: Sep 29 Filed by: Boudes Pol F

Oct 3, 2023 05:01 PM Form 4 Protalix BioTherapeutics For: Sep 29 Filed by: Schwartz Aharon

Oct 3, 2023 05:01 PM Form 4 Protalix BioTherapeutics For: Sep 29 Filed by: Bar-Shalev Amos

Sep 15, 2023 04:47 PM Form 4 Protalix BioTherapeutics For: Sep 14 Filed by: Forster Eliot

Sep 15, 2023 04:46 PM Form 3 Protalix BioTherapeutics For: Sep 14 Filed by: Forster Eliot

Sep 12, 2023 06:59 AM Form 8-K Protalix BioTherapeutics For: Sep 12

Sep 12, 2023 06:50 AM Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

Sep 6, 2023 06:50 AM Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 17, 2023 04:31 PM Form 4 Protalix BioTherapeutics For: Aug 15 Filed by: Bashan Dror

Aug 17, 2023 04:31 PM Form 4 Protalix BioTherapeutics For: Aug 15 Filed by: Hayon Yael

Aug 17, 2023 04:31 PM Form 4 Protalix BioTherapeutics For: Aug 15 Filed by: Rubin Eyal

Aug 17, 2023 04:30 PM Form 4 Protalix BioTherapeutics For: Aug 15 Filed by: Naos Yaron

Aug 11, 2023 04:32 PM Form S-8 Protalix BioTherapeutics

Aug 7, 2023 07:03 AM Form 10-Q Protalix BioTherapeutics For: Jun 30

Aug 7, 2023 06:59 AM Form 8-K Protalix BioTherapeutics For: Aug 07

Aug 7, 2023 06:52 AM Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.16

Aug 7, 2023 06:50 AM Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results

Aug 1, 2023 06:50 AM Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jul 31, 2023 06:50 AM Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023

Jul 13, 2023 04:42 PM Form 8-K Protalix BioTherapeutics For: Jul 13

Jul 7, 2023 04:31 PM Form 424B3 Protalix BioTherapeutics

Jun 29, 2023 07:25 AM Form 8-K Protalix BioTherapeutics For: Jun 28

Jun 28, 2023 04:30 PM Form DEFA14A Protalix BioTherapeutics

Jun 8, 2023 06:50 AM Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease

May 30, 2023 07:24 AM Form 8-K Protalix BioTherapeutics For: May 30

May 30, 2023 06:52 AM Protalix BioTherapeutics (PLX) issues letter to shareholders

May 30, 2023 06:50 AM Protalix BioTherapeutics Issues Letter to Stockholders

May 23, 2023 06:52 AM Protalix BioTherapeutics (PLX) to Join Russell 3000 Index

May 23, 2023 06:50 AM Protalix BioTherapeutics set to join Russell 3000® Index